Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus-Reference-Cited by-同舟云学术

Monoclonal Antibody Therapy Protects Pharmacologically Immunosuppressed Mice from Lethal Infection with Influenza B Virus

Published:2020-08-20 Issue:9 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Marathe Bindumadhav M.¹,Asthagiri Arunkumar Guha²³^ORCID,Vogel Peter⁴,Pascua Philippe Noriel Q.¹,Jones Jeremy¹,Webby Richard J.¹,Krammer Florian²^ORCID,Govorkova Elena A.¹^ORCID

Affiliation:

1. Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA

2. Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA

3. Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA

4. Veterinary Pathology Core, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA

Abstract

Human influenza A and B viruses are highly contagious and cause similar illnesses and seasonal epidemics. Currently available antiviral drugs have limited efficacy in humans with compromised immune systems; therefore, alternative strategies for protection are needed. Here, we investigated whether monoclonal antibodies (MAbs) targeting hemagglutinin (HA) and/or neuraminidase (NA) proteins would protect immunosuppressed mice from severe infections with influenza B virus. Pharmacologically immunosuppressed BALB/c mice were inoculated with B/Brisbane/60/2008 (BR/08) influenza virus and were treated with a single dose of 1, 5, or 25 mg/kg of body weight per day of either an anti-HA MAb (1D2) or an anti-NA MAb (1F2) starting at 24 hours postinoculation (hpi).

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00284-20

Reference50 articles.

1. World Health Organization. 2019. Influenza (seasonal). World Health Organization, Geneva, Switzerland. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal).

2. Universal influenza virus vaccines and therapeutics: where do we stand with influenza B virus?

3. Centers for Disease Control and Prevention. 2019. FluView: weekly U.S. influenza surveillance report. Centers for Disease Control and Prevention, Atlanta, GA. https://www.cdc.gov/flu/weekly/index.htm.

4. Influenza-Associated Pediatric Deaths in the United States, 2010–2016

5. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2019–20 Influenza Season

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. H1N1 nanobody development and therapeutic efficacy verification in H1N1-challenged mice;Biomedicine & Pharmacotherapy;2024-07

2. Dual neutralization of influenza virus hemagglutinin and neuraminidase by a bispecific antibody leads to improved antiviral activity;Molecular Therapy;2024-07

3. A comprehensive review of highly pathogenic avian influenza (HPAI) H5N1: An imminent threat at doorstep;Travel Medicine and Infectious Disease;2023-09

4. Dual neutralization of influenza virus hemagglutinin and neuraminidase by a bispecific antibody leads to improved antiviral activity;2023-03-20

5. Preclinical and clinical developments for combination treatment of influenza;PLOS Pathogens;2022-05-12